Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,380,600.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $69.03, for a total value of $1,380,600.00. Following the transaction, the chief executive officer owned 733,719 shares of the company’s stock, valued at $50,648,622.57. This represents a 2.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Helen Torley also recently made the following trade(s):

• On Wednesday, October 1st, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $75.35, for a total value of $1,507,000.00.
• On Wednesday, September 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $74.44, for a total transaction of $1,488,800.00.
• On Tuesday, August 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $63.51, for a total transaction of $1,270,200.00.
• On Wednesday, July 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $56.43, for a total transaction of $1,128,600.00.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $68.98 on Monday. The company’s 50-day moving average price is $70.45 and its 200-day moving average price is $61.93. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. The company has a market cap of $8.07 billion, a PE ratio of 15.78, a price-to-earnings-growth ratio of 0.37 and a beta of 1.16. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. During the same quarter last year, the firm earned $0.91 EPS. The firm’s revenue for the quarter was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Institutional Trading of Halozyme Therapeutics

A number of institutional investors have recently modified their holdings of HALO. Isthmus Partners LLC raised its stake in shares of Halozyme Therapeutics by 2.5% during the 1st quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company’s stock worth $439,000 after acquiring an additional 169 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Halozyme Therapeutics by 6.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 174 shares in the last quarter. OneDigital Investment Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 1.7% during the 1st quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company’s stock valued at $649,000 after purchasing an additional 175 shares during the last quarter. Park Place Capital Corp boosted its position in shares of Halozyme Therapeutics by 20.1% in the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 182 shares in the last quarter. Finally, Xponance Inc. grew its stake in Halozyme Therapeutics by 1.1% during the 1st quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company’s stock worth $1,190,000 after buying an additional 198 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. boosted their target price on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a research report on Thursday, August 7th. Weiss Ratings reissued a “hold (c+)” rating on shares of Halozyme Therapeutics in a research note on Saturday, September 27th. Benchmark raised their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. JMP Securities upped their price target on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a report on Wednesday, August 6th. Finally, The Goldman Sachs Group assumed coverage on shares of Halozyme Therapeutics in a research note on Thursday, July 10th. They issued a “neutral” rating and a $55.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $70.44.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.